Cancer Family
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
CI-CAN-00000039Explore in graph →
Non-malignant864 active trials6 approved drugs159 evidence items
- NCIt
- C35562
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000039Explore in graph →
Regulatory
39 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Dabrafenib | EU EMA | High-Grade Glioma, NOS | Low-grade glioma Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. High-grade glioma Finlee in combination with trametinib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment. | approved | Nov 15, 2023 | ema |
| Entrectinib | EU EMA | Tumor-agnosticLung Non-Small Cell Carcinoma | Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options. Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.conditional | approved | Jul 31, 2020 | ema |
| Larotrectinib | EU EMA | Tumor-agnostic | Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options. |
Data updated 16 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Temozolomide | 16 | 13 | 3 |
| Vemurafenib | 16 | 14 | 1 |
| Selumetinib | 14 | 14 | 0 |
| Entrectinib | 13 | 13 | 0 |
| Trametinib | 13 | 13 | 0 |
| Erlotinib | 12 | 12 | 0 |
| Bevacizumab | 8 | 7 | 1 |
| Dabrafenib | 6 | 6 | 0 |
| Afatinib | 5 | 5 | 0 |
| Everolimus | 5 | 4 | 0 |
| Gefitinib | 5 | 4 | 1 |
| Larotrectinib | 5 | 5 | 0 |
| Pacritinib | 5 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| approved |
| Sep 19, 2019 |
| ema |
| Repotrectinib | EU EMA | Tumor-agnosticLung Non-Small Cell Carcinoma | Augtyro as monotherapy is indicated for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). Augtyro as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with advanced solid tumours expressing a NTRK gene fusion, and who have received a prior NTRK inhibitor, or have not received a prior NTRK inhibitor and treatment options not targeting NTRK provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1)conditional | approved | Jan 13, 2025 | ema |
| Selpercatinib | EU EMA | Tumor-agnostic | Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. For biomarker-based patient selection, see section 4.2. Retsevmo as monotherapy is indicated for the treatment of adults and paediatric patients 2 years of age and older with: advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) . For biomarker-based patient selection, see section 4.2. advanced RET mutant medullary thyroid cancer (MTC) . For biomarker-based patient selection, see section 4.2. advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1). For biomarker-based patient selection, see section 4.2. | approved | Feb 11, 2021 | ema |
| Temozolomide | EU EMA | Glioblastoma | Temozolomide Sun is indicated for the treatment of: adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment; children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. | approved | Jul 13, 2011 | ema |
| Temozolomide | EU EMA | Glioblastoma | For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. | approved | Mar 15, 2010 | ema |
| Temozolomide | EU EMA | Glioblastoma | For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. | withdrawn | Mar 15, 2010 | ema |
| Temozolomide | EU EMA | Glioblastoma | For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. | withdrawnsince Sep 15, 2022 | Mar 15, 2010 | ema |
| Temozolomide | EU EMA | Glioblastoma | For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. | approved | Jan 28, 2010 | ema |
| Temozolomide | EU EMA | Glioblastoma | Temomedac hard capsules is indicated for the treatment of: adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment; children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. | approved | Jan 25, 2010 | ema |
| Temozolomide | EU EMA | Glioblastoma | Temodal hard capsules is indicated for the treatment of: adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment; children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. | approved | Jan 26, 1999 | ema |
| Trametinib | EU EMA | High-Grade Glioma, NOS | Low-grade glioma Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. High-grade glioma Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment. | approved | Jan 5, 2024 | ema |
| 5 |
| 0 |
| Dordaviprone | 4 | 4 | 0 |
| Lapatinib | 4 | 4 | 0 |
| Vorasidenib | 4 | 4 | 0 |
| Adavosertib | 3 | 3 | 0 |
| Buparlisib | 3 | 3 | 0 |
| Cetuximab | 3 | 3 | 0 |
| Olaparib | 3 | 3 | 0 |
| Osimertinib | 3 | 3 | 0 |
| Palbociclib | 3 | 2 | 1 |
| Pexidartinib | 3 | 3 | 0 |
| AGI-5198 | 2 | 2 | 0 |
| ALK2 Inhibitor LDN-193189 | 2 | 2 | 0 |
| Carboplatin | 2 | 2 | 0 |
| Cobimetinib | 2 | 2 | 0 |
| Crizotinib | 2 | 2 | 0 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 2 | 2 | 0 |
| Erdafitinib | 2 | 2 | 0 |
| Lomustine | 2 | 2 | 0 |
| Nivolumab | 2 | 1 | 1 |
| Pembrolizumab | 2 | 1 | 1 |
| Sunitinib | 2 | 2 | 0 |
| Talazoparib | 2 | 2 | 0 |
| Tovorafenib | 2 | 2 | 0 |
| Vincristine | 2 | 2 | 0 |
| 3-Dimensional Conformal Radiation Therapy | 1 | 1 | 0 |
| Antisecretory Factor-enriched Egg Yolk Powder Supplement | 1 | 1 | 0 |
| Bevacizumab/Lomustine Regimen | 1 | 1 | 0 |
| Carmustine | 1 | 1 | 0 |
| Dacomitinib | 1 | 1 | 0 |
| Dasatinib | 1 | 1 | 0 |
| Dovitinib | 1 | 1 | 0 |
| Fexagratinib | 1 | 1 | 0 |
| Futibatinib | 1 | 1 | 0 |
| JQ1 Compound | 1 | 1 | 0 |
| Lorlatinib | 1 | 1 | 0 |
| MEK-1/MEKK-1 Inhibitor E6201 | 1 | 1 | 0 |
| MET Tyrosine Kinase Inhibitor SGX523 | 1 | 1 | 0 |
| Navtemadlin | 1 | 1 | 0 |
| Nimotuzumab | 1 | 1 | 0 |
| O6-Benzylguanine | 1 | 1 | 0 |
| Onalespib | 1 | 1 | 0 |
| Pan-Mutant-IDH1 Inhibitor Bay-1436032 | 1 | 1 | 0 |
| PCV Regimen | 1 | 1 | 0 |
| Pemigatinib | 1 | 1 | 0 |
| PLX4720 | 1 | 0 | 0 |
| Pyridostatin | 1 | 1 | 0 |
| Radiation Therapy | 1 | 1 | 0 |
| RG7112 | 1 | 1 | 0 |
| Rindopepimut | 1 | 1 | 0 |
| Safusidenib | 1 | 1 | 0 |
| Sorafenib | 1 | 0 | 1 |
| Tipifarnib | 1 | 1 | 0 |
| Tyrphostin AG 1478 | 1 | 1 | 0 |
| Vatalanib | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.